e-learning
resources
Virtual 2020
Pre-Congress Content
Clinical and laboratory pharmacology in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma
A. Silberbrandt (Copenhagen, Denmark), M. Mukherjee (Hamilton, Canada), M. Hvidtfeldt (Copenhagen, Denmark), L. Frøssing (Copenhagen, Denmark), P. Nair (Hamilton, Canada), C. Porsbjerg (Copenhagen, Denmark)
Source:
Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Session:
Clinical and laboratory pharmacology in asthma
Session type:
E-poster session
Number:
1412
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Silberbrandt (Copenhagen, Denmark), M. Mukherjee (Hamilton, Canada), M. Hvidtfeldt (Copenhagen, Denmark), L. Frøssing (Copenhagen, Denmark), P. Nair (Hamilton, Canada), C. Porsbjerg (Copenhagen, Denmark). Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma. 1412
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Source: International Congress 2017 – Asthma management
Year: 2017
Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008
Heterogeneous response of airway eosinophilia to biologics in severe asthma patients
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Outcome of COPD exacerbations treated with and without oral steroids in relation to airway and systemic inflammation
Source: Eur Respir J 2005; 26: Suppl. 49, 283s
Year: 2005
Short-term treatment with sistemic corticosteroids blunted neutrophilic airway response to ozone in mild asthmatics
Source: Eur Respir J 2002; 20: Suppl. 38, 569s
Year: 2002
Oral corticosteroids in the treatment of exacerbation of severe asthma
Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden
Year: 2020
Persistent airway inflammation in young allergic wheezing children treated with inhaled corticosteroids
Source: Annual Congress 2003 - Current issues on wheezing in infancy
Year: 2003
Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
The effects of two weeks of repeated low-dose allergen exposure on sputum eosinophilic and neutrophilic inflammation in atopic asthma: protection by inhaled steroids?
Source: Eur Respir J 2001; 18: Suppl. 33, 482s
Year: 2001
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Source: Eur Respir J 2006; 27: 964-971
Year: 2006
Evidence of a distinct phenotype of adult onset asthma characterized by an airway neutrophilia and poor response to inhaled corticosteroids
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: Eur Respir J, 49 (6) 1700848; 10.1183/13993003.00848-2017
Year: 2017
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: Eur Respir J 2017; 49(1): 1600839; DOI: 10.1183/13993003.00839-2016
Year: 2017
The importance of early applying inhaled corticosteroids in patients with mild bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 57s
Year: 2002
Effect of an inhaled alpha4-antagonist on the allergen-induced late asthmatic response in patients with mild asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 135s
Year: 2005
Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept